Saturday, October 31, 2026

Upland Software Stock Declines 32% In 21 Sessions: What Could Be The Cause?

Via News Just in

August 28, 2023

Upland Software Stock Declines 32% In 21 Sessions: What Could Be The Cause?
(VIANEWS) - Upland Software (UPLD) experienced an astounding drop of 32.53% over 21 days from its previous closing price of EUR3.75 to EUR2.53 as of 07:35 EST on Monday. Two consecutive sessions saw losses. While overall performance in the NASDAQ index increased 0.94% to EUR13,590.65, Upland Software lagged behind. As it now trades 78% below its 52-week high of EUR11.88 which it hit back on 2023-03-14, performance remains subpar for this stock.

About Upland Software

Upland Software, Inc. is a premier cloud-based enterprise work management provider for organizations operating throughout North America (US, UK and Canada), Europe and Australia. Upland offers an expansive suite of software applications under its flagship Upland brand that serve multiple industries, including marketing, sales, contact center operations management, project management IT business operations HR/legal. Upland offers more than software solutions; we also offer professional services including implementation, integration, training and customer support. Upland Software Inc. serves a diverse clientele that spans global corporations to government agencies to small and medium-sized businesses in various sectors like finance, consulting, technology manufacturing media telecommunication politics healthcare life sciences retail hospitality etc. Established in 2010 in Austin Texas as Silverback Enterprise Group Inc, this company changed to Upland Software in November 2013 when they rebranded.

Yearly Analysis

Upland Software's current stock price of EUR2.53 is far below its 52-week high of EUR11.88, signalling significant value erosion. Yet it is higher than its 52-week low of EUR2.47; and this year's anticipated sales decline (-6.3%) and next year (-0.2%) indicate positive earnings potential at Upland Software despite negative sales projections (-6.2%) and negative EBIDTA projections of 1.46 suggesting positive profits generated. Investors should tread cautiously when considering Upland Software at its current price, given its negative sales growth expectations and positive EBITDA margin. But investors may wish to consider investing long-term, keeping close tabs on Upland's financial performance and market conditions before making any definitive investment decisions.

Technical Analysis

Upland Software stock has experienced a steady downward trend, as evidenced by its price being significantly below both its 50-day and 200-day moving averages. This may indicate bearish sentiment among investors leading to diminished demand for the stock, which may also be supported by its trading volume being 77.51% lower than average; suggesting investors may have lost interest. Upland Software has experienced relatively low volatility despite bearish sentiment, with its intraday variation averages being positive in each of the past week, month, and quarter. However, its highest average weekly amplitude volatility of 4.47% suggests there may be potential for price swings either way. Based on its stochastic oscillator reading of at least 80, Upland Software stock is considered overbought with regards to investors having extended themselves with bullish positions that may require correction. Upland Software stock has recently experienced a downward trend, marked by bearish investor sentiment, low trading volume and potential price swing due to overbought conditions. Investors should keep close tabs on these indicators and consider taking a cautious approach with regards to investing in Upland Software.

Quarter Analysis

Upland Software appears to be on an unfavorable financial trajectory based on available information. Negative sales growth for both the current and coming quarter, combined with negative growth estimates suggest the company may be facing challenges in generating revenue. An annual decrease of 7.1% is cause for alarm, especially given negative growth estimates for the next quarter. It signals that demand may have diminished for their products or services and could have serious repercussions for financial performance long term. Given this outlook, prospective investors should carefully assess the risks involved with investing in Upland Software given its current economic climate and COVID-19 pandemic's effects on various industries. It may be prudent to conduct additional research and analysis such as reviewing Upland's financial statements or management team prior to making any investment decisions.

Equity Analysis

Upland Software reported an Earnings Per Share (EPS) loss for the last twelve months at -EUR5.86 per share, signifying they have suffered an operating loss over this time frame. Upland Software's Return on Equity (ROE) of negative -62.01% for the twelve trailing months could indicate that shareholders have not seen enough returns relative to what was invested into Upland Software compared to how much equity is available for investment in return. This may cause concern for potential investors. Notably, these figures reflect performance from a period prior to 12 months ago and it may have improved or declined since. Therefore, potential investors would do well to conduct additional research before making investment decisions. More news about Upland Software (UPLD).
Via News Just in

Breaking news and real-time updates on financial markets, business developments, and economic events from Via News.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com